| INTRODUC TI ON

Hepatitis B virus (HBV) is a hepadnavirus with a well-demonstrated
capacity to increase morbidity and mortality in humans. After infection, patients develop antibodies directed toward numerous viral antigens and most of them acquire long-term immunity translated by sustained antibody titers. Progression to chronicity following infection with HBV is strongly associated with age at infection. While vertical transmission leads to chronic infection in 90% of cases, the likelihood of progression to chronicity is approximately 5% in immunocompetent adults. 1 Globally, nearly 3.5% of the global population (257 million people) is chronically infected with HBV. 2 Considering the higher prevalence of HBV infection in patients with end-stage renal disease when compared with the general population, previous HBV infection is common in kidney transplant (KT) recipients with an overall rate of 2.2%-20.9%. 3 Furthermore, active HBV infection is associated with increased morbidity, mortality, and reduced graft survival after KT. 4 Hepatitis B virus reactivation is possible in patients with chronic or past HBV infection and can be mild and asymptomatic or severe, leading to liver failure or hepatocellular carcinoma. 5 Possible sources of HBV detection in hepatitis B surface antigen (HBsAg)-negative patients are reactivation of previous HBV infection, 6 transmission from occult HBV donors, or transmission after KT through sexual contact or blood transfusions.
Patients unveiling serologic evidence of past HBV infection Reactivation can occur both through the suppression of T cells, the predominant control mechanism, or the suppression of B cells and antibody production. 7 Furthermore, direct stimulation of gene expression through the glucocorticoid-responsive element of the HBV genome is also relevant for viral reactivation. 8 Hepatitis B virus reactivation can be defined as a viral load >2000 IU/mL 9 or as a sudden and rapid increase in HBV DNA level by at least 100-fold in patients with previously detectable HBV DNA or reappearance of HBV DNA viremia in patients who did not have viremia before immunosuppressive therapy. 10 Reverse seroconversion defines the reappearance of HBsAg and HBV DNA in patients with serological markers of previous contact with HBV. 10 Hepatitis B virus reactivation can occur at any time after the introduction of immunosuppressive therapies and can lead to life-threatening complications. The chance of HBV reactivation is usually related to the infection status and the type and degree of immunosuppression.
11
Previous studies conducted in this subset of patients showed conflicting results on the risk of HBV reactivation. 6, [11] [12] [13] [14] [15] Several aspects related to HBV reactivation remain unclear: in whom to prescribe HBV prophylactic agents; which agent to prescribe and for which period; and who should be monitored instead of receiving prophylaxis. Thus, the American Gastroenterological Association (AGA) Institute recently published a guideline on the prevention and treatment of HBV reactivation during immunosuppressive drug therapy. 16 Nevertheless, as the guideline has not addressed the issue of HBV reactivation in solid organ transplantation, it remains unclear how to follow this subset of patients in the post transplant period.
This study retrospectively evaluates the clinical and virologic course of a cohort of KT recipients with prior resolved HBV infection.
| ME THODS
| Study population
Retrospective cohort study included 631 patients who underwent
KT between August 2007 and December 2016 at a kidney transplant center in Portugal. All patients were retrospectively evaluated and only recipients with serological markers of resolved HBV infection at the time of KT were included in the cohort analysis. Patients were followed until April 2018.
Resolved HBV infection was defined as HBsAg negative and antiHBc positive before KT, regardless of hepatitis B surface antibody (anti-HBs) status, in addition to liver enzymes in the normal range.
HBV reactivation was defined as HBV DNA viral load >2000 IU/mL, according to recent guidelines.
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Exclusion criteria were: positivity for HBsAg before KT, abnormal aminotransferases before KT, evidence of active HBV-related hepatitis previously to KT, or loss of follow-up. and the presence of a previous KT were collected at the baseline.
| Data collection
Induction and maintenance immunosuppression, length of follow up, biopsy-proven acute rejection episodes, incidence of impaired liver function, and causes of graft loss and mortality were also collected.
Outcome data included HBV reactivation, death-censored graft survival, and patient survival. Graft failure was defined as an estimated glomerular filtration rate <15 mL/min/1.73 m 2 calculated by CKD-EPI formula. Positivity for anti-HBs was considered for a titer over 10 IU/L. 
| Immunosuppressive regimen
Recipients received basiliximab, antithymocyte globulin, or a combination of antithymocyte globulin and rituximab as induction therapy.
Basiliximab (20 mg IV) was administered in the first and fourth day after KT; antithymocyte globulin (1.25 mg/kg/d IV) was administered since the first day and usually until the seventh day after KT;
rituximab was prescribed at a single dose (375 mg/m 2 ) prior to KT.
Methylprednisolone (500 mg, 1st day; 250 mg, 2nd day; 125 mg, 3rd
day; 80 mg, 4th day IV after KT) was included in all immunosuppressive induction regimens.
The choice of the immunosuppressive regimen depended, mainly, on patient′s immunologic profile (percentage of panel reactive antibodies, number of HLA mismatches with the donor, preformed donor-specific antibodies) and cold ischemia time.
The maintenance immunosuppressive therapy included, in most patients, tacrolimus, mycophenolate mofetil, and prednisone.
Tacrolimus was administered orally at 0.15 mg/kg/d divided into two doses and adjusted to maintain a target trough concentration between 4 and 10 ng/mL, depending on the time elapsed after KT.
Prednisolone was prescribed since the fifth day after KT (0.6 mg/ kg) and was tapered to 5 mg/d during the first 3 months after KT.
Mycophenolate mofetil (1000 mg orally twice daily) was started after KT and was reduced if adverse events appeared; it was reduced to 1000-1500 mg daily dose after the first 3-6 months.
Acute cellular rejection (ACR) was treated with methylprednisolone (500 mg/d IV) for 3 days. Antithymocyte globulin was prescribed in steroid-resistant ACR or more aggressive histological cellular rejections. Antibody-mediated rejection (AMR) was treated with a variable combination of plasmapheresis, intravenous immunoglobulin, and/or rituximab.
| Prophylaxis regimens
All patients received trimethoprim/sulfamethoxazole (480 mg/d, adjusted to kidney function) and Pneumocystis jirovecii infection prophylaxis for 1 year after KT.
Valganciclovir (900 mg/d, adjusted to kidney function) was given to patients who received antithymocyte globulin and/or rituximab and in CMV IgG-negative recipient/CMV IgG-positive donor pairs for 6 months.
Hepatitis B virus antiviral agents were not prophylactically given to anti-HBc-positive patients. 
| Statistical analysis
| RE SULTS
| Patient's characteristics
Of the 631 KT recipients, 70 (11.1%) were eligible for inclusion in this study. All were single organ recipients and 7 (10%) received a graft from an anti-HBc positive/anti-HBs positive donor. General demographic data and patient′s baseline characteristics are described in 
| HBV reactivation
Eleven patients ( All the remaining patients were negative to HBsAg and HBV DNA. 
| Clinical outcomes
| D ISCUSS I ON
The rates of HBV reactivation after KT in HBsAg-positive patients reached 94% before the introduction of antiviral prophylaxis. 5 Several studies showed that HBsAg positivity was an independent risk factor for all-cause mortality and graft failure. 18 Fortunately, the introduction of antiviral prophylaxis in HBsAg-positive patients has greatly improved transplant outcomes.
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Initial HBV infection is followed by the development of host immunity, which drives the course of the infection and its complications. 20 Most patients become HBsAg negative and, initially, it has been assumed that those patients had cleared the virus. Later, it was understood that the subgroup of HBsAg-negative/anti-HBc-positive patients remain infectious. 21 These patients have been recognized to be latently infected with an episomal form of HBV, persisting with ongoing viral replication and a few nucleotide mutations in the precore and core regions. 22 Thus, viral replication persists in the liver of individuals with prior HBV infection.
In our study, the rate of HBV reactivation after KT in patients Hepatitis B virus reactivation is more likely than reinfection with a different strain in the two patients we present due to the lack of risk factors for de novo HBV infection and the absence of HBV serological markers in the donors. Analysis of pretransplant HBV DNA could give additional information, but, unfortunately, pretransplant serum samples of these patients were unavailable. The absence of genotype testing in patients which experienced HBV reactivations precludes us to completely rule out the possibility of reinfection.
Immunosuppression is an important risk factor for HBV reactivation but, unfortunately, little attention has been given to solid organ transplant patients with previously resolved HBV infection.
The incidence of HBV reactivation in these patients is unclear and may depend on many causes including host characteristics, virologic factors and type and degree of immunosuppression.
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A growing number of publications suggest that the use of rituximab to treat hematologic malignancies increases the risk of reactivation in HBsAg-negative/anti-HBc-positive patients [24] [25] [26] and one recent publication stated that rituximab desensitization for incompatible KT also significantly increased the risk of HBV reactivation, mainly in patients who were both anti-HBc positive and anti-HBs negative at the time of transplantation. 27 The relationship between other immunosuppressants used in KT and HBV reactivation is less consistent. AGA Institute recently published a guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive therapy. 16 It was assessed that HBV reactivation risk depends on the use of specific immunosuppressants. The high-risk group of patients for HBV reactivation includes HBsAg-negative/anti-HBc-positive patients treated with B-cell-depleting agents. Rituximab is considered to have the most elevated risk for HBV reactivation from all immunosuppressants used in KT, as more than 10% of treated patients develop this problem. 16 The risk of reactivation may continue up to 12 months, considering the prolonged duration of the immune reconstitution.
On the other hand, patients with occult HBV infection treated 
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Even though anti-HBs antibody can prevent the entry of HBV into hepatocytes, current guidelines suggest against using anti-HBs status to guide antiviral prophylaxis for the prevention of HBV reactivation in immunosuppressed patients. 16 However, some studies have defended that anti-HBs could confer protection against reactivation. 15, 27 Since in our study 94.3% of patients showed positivity to anti-HBs and sequential monitoring of anti-HBs titers remained stable during follow up, regardless of the immunosuppressive regimen, we could not estimate the protective effect of anti-HBs antibodies.
Curiously, one patient experienced HBV reactivation without disappearance of anti-HBs antibodies, so an anti-HBs titer >100 mUI/mL was not protective in this case.
Additionally, it is still unclear whether prophylactic use of anti- Although strong data support that antiviral therapy is more efficacious when initiated prior to or at the start of immunosuppressive therapy, scant data are available to inform when antiviral therapy can be stopped. Since immunosuppression in KT patients is for life and reactivations can occur any time after KT, it is difficult to predict when to stop antiviral prophylaxis.
We routinely perform serological HBV testing, but, until recently, we did not regularly measure HBV DNA viral load. Current As far as we know, with a median follow up of 12.5 years, this is one of the largest longitudinal studies in KT recipients with a past HBV infection. Also, it is one of the few publications where a cohort of European patients has been studied to evaluate the rate of HBV reactivation.
However, we recognize this study's limitations: most of our patients showed positive anti-HBs prior to KT, so it was difficult to estimate the protective effect of preoperative anti-HBs and, although the serological data were obtained according a previously established protocol, its analysis was retrospective. Also, the duration of follow up after reactivation is short.
In conclusion, we have shown that HBV reactivation after KT, although rare, is possible. As only a small number of patients experienced 
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